InvestorsHub Logo
Followers 150
Posts 15047
Boards Moderated 1
Alias Born 07/07/2002

Re: None

Tuesday, 01/29/2013 8:07:39 AM

Tuesday, January 29, 2013 8:07:39 AM

Post# of 5874
LOS ANGELES, Jan 29, 2013 (BUSINESS WIRE) -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the US Food and Drug Administration (FDA) has allowed the investigational new drug (IND) application for ICT-140, paving the way for conducting a clinical trial. ICT-140 is a dendritic cell vaccine targeting seven antigens that are over-expressed in ovarian cancer, as well as cancer stem cells. ImmunoCellular filed the IND application with the FDA in the fourth quarter of 2012, as planned.